ReviewJournal of thoracic disease2018
Machine perfusion of thoracic organs.
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 59 citations in OpenAlex.
- Cell therapy strategies for organ regeneration.BMC medicine · 2026Review
- Is Time Scheduling Important? An Analysis of Donor Heart Cross-clamp Times During Heart Transplantation.Transplantation direct · 2024Article
- Review
- European Society of Organ Transplantation (ESOT) Consensus Statement on Machine Perfusion in Cardiothoracic Transplant.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Uncontrolled Donation after Circulatory Death Only Lung Program: An Urgent Opportunity.Journal of clinical medicine · 2023Review
- A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome.Cells · 2022Review
- Ex-Vivo Preservation with the Organ Care System in High Risk Heart Transplantation.Life (Basel, Switzerland) · 2022Article
- Article
- Expanding controlled donation after the circulatory determination of death: statement from an international collaborative.Intensive care medicine · 2021Article
- Subnormothermic ex vivo lung perfusion attenuates ischemia reperfusion injury from donation after circulatory death donors.PloS one · 2021Article
- Flow-controlled ventilation during EVLP improves oxygenation and preserves alveolar recruitment.Intensive care medicine experimental · 2020Article
- Isolated Lung Perfusion in the Management of Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2020Review
- Optimizing organs for transplantation; advancements in perfusion and preservation methods.Transplantation reviews (Orlando, Fla.) · 2020Review
- Transplanting Marginal Organs in the Era of Modern Machine Perfusion and Advanced Organ Monitoring.Frontiers in immunology · 2020Review
- Genetic Engineering of the Kidney to Permanently Silence MHC Transcripts DuringFrontiers in immunology · 2020Article
- Bioengineering approaches to organ preservation ex vivo.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- The donor heart and organ perfusion technology.Journal of thoracic disease · 2019Review
- Review
- Complement Therapeutics in the Multi-Organ Donor: Do or Don't?Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article summarizes recent knowledge and clinical advances in machine perfusion (MP) of thoracic organs. MP of thoracic organs has gained much attention during the last decade. Clinical studies are investigating the role of MP to preserve, resuscitate, and assess heart and lungs prior to transplantation. Currently, MP of the cardiac allograft is essential in all type DCD heart transplantation while MP of the pulmonary allograft is mandatory in uncontrolled DCD lung transplantation. MP of thoracic organs also offers an exciting platform to further investigate downregulation of the innate and adaptive immunity prior to reperfusion of the allograft in recipients. MP provides a promising technology that allows pre-transplant preservation, resuscitation, assessment, repair, and conditioning of cardiac and pulmonary allografts outside the body in a near physiologic state prior to planned transplantation. Results of ongoing clinical trials are awaited to estimate the true clinical value of this new technology in advancing the field of heart and lung transplantation by increasing the total number and the quality of available organs and by further improving recipient early and long-term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.